The office visit is the front door. The endoscopy suite is the business.
GI economics sit in procedure throughput, site of service, and the office-to-procedure conversion in between. A practice can look busy in clinic while the suite runs under capacity, and the margin difference between those two months is significant. The monthly briefing reads clinic volume, procedure conversion, endoscopy utilization, and ancillary lines together so you can see where the constraint actually is.
Where the specialty stands
GI is a procedure-driven specialty under steady fee-schedule pressure, with screening colonoscopy guidelines now reaching age 45 and a growing pipeline of biologics for IBD. Independent groups are consolidating into platforms while ASC ownership and ancillary lines (anesthesia, pathology, infusion) remain the durable margin story.
- USPSTF screening start age at 45 is still expanding the eligible pool, especially in commercially insured panels.
- Private equity-backed GI platforms continue to roll up regional groups; independence requires deliberate scale and governance choices.
- Anesthesia and pathology in-house captures, plus infusion suites for biologics, are where margin is being built or lost.
- Prior authorization burden for biologics keeps climbing. Staffing the authorization workflow is now an operational measure in its own right.
- AI-assisted polyp detection (CADe) is being adopted unevenly; ROI is real but requires endoscopist buy-in and case-mix.
What the briefing reads for a gastroenterology practice
Room hours used against room hours available, turnover time, and cases per block. Unused block time is the most expensive idle asset in a GI practice.
How many new consults become scheduled procedures, and how long the gap is. A lengthening gap usually points at scheduling capacity, prep instructions, or authorization delay.
In-office, ASC, and hospital outpatient tracked separately, including facility versus professional collections. Payer steering can move margin without changing case volume at all.
Same-day cancellations, inadequate preps, and no-shows in the procedure schedule. Each open procedure slot costs several times an open clinic slot.
Anesthesia arrangements, pathology, and infusion where applicable, read on their own contribution rather than blended into total revenue.
Coverage and cost-sharing rules for screening colonoscopy shape both volume and collections. Policy changes here move patient balances as much as payer payments.
Illustrative reference ranges
Read the methodologyThese internally authored, industry-informed estimates provide specialty context. They are not live peer data, licensed survey medians, targets, or promises.
| Indicator | Lower reference | Central reference | Upper reference |
|---|---|---|---|
| Revenue per provider (monthly) | $60k | $75k | $90k |
| Scheduling efficiency | 73% | 80% | 88% |
| Average reimbursement rate | 62% | 70% | 78% |
| Contractual adjustment rate | 26% | 32% | 38% |
| Days in A/R | 30 days | 38 days | 46 days |
| No-show rate | 5% | 7.4% | 10% |
| Net collection rate | 93.5% | 96.2% | 98% |
| Commercial payer mix | 50% | 64% | 76% |
| Third next available appointment | 10 days | 15 days | 22 days |
| Staff per provider | 2 | 2.5 | 3 |
| Provider turnover | 4% | 8% | 12% |
| Training investment (% of payroll) | 1.2% | 2% | 2.8% |
| Operating expense ratio | 60% | 66% | 72% |
| Cost per visit | $185 | $220 | $260 |
| Patient satisfaction | 4.2 / 5 | 4.5 / 5 | 4.7 / 5 |
| Quality compliance rate | 88% | 93% | 96% |
Questions this briefing is built to answer
- Is our endoscopy suite running at the utilization we are paying for?
- How long does it take a new consult to become a completed procedure?
- What is each site of service actually contributing after direct cost?
- How much revenue do cancellations and inadequate preps cost us each month?
- Is our anesthesia arrangement still the right economic structure?
- Are patient balances growing faster than payer receivables?
What we read to stay current
See what this looks like for your practice
Send aggregate practice data for a recent period and we will show you the executive brief format: what changed, why it may matter, likely drivers, and what to watch.
AileronMD analyzes business, financial, and operational data only. Do not submit patient records or protected health information. AileronMD does not provide clinical or medical advice, and does not guarantee financial results. Guidance is advisory; practice leadership makes the decisions.